Product
bb2121
Aliases
BMS-986395
4 clinical trials
1 indication
Indication
Multiple MyelomaClinical trial
A Phase 2, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2023-12-20
Clinical trial
A Phase 2, Multi-cohort, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clinical High-Risk Multiple Myeloma (KarMMa-2)Status: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
A Phase 1, Open-label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (KarMMa-4)Status: Completed, Estimated PCD: 2023-06-07
Clinical trial
CRB-401 A Phase 1 Study of bb2121 in BCMA-Expressing Multiple MyelomaStatus: Completed, Estimated PCD: 2019-07-22